KRTAP9-4

Across TCGA pan-cancer cohorts, KRTAP9-4 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated KRTAP9-4 data layer compared with 15 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher KRTAP9-4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated KRTAP9-4 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BLCA, COAD, and UCEC are the cancer types where KRTAP9-4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.051	0.720	<.001	48	view →
COAD	OS	Median	All	0.348	0.872	<.001	24	view →
UCEC	DFS	Median	II,III,IV	1.000	0.487	.035	16	view →
LUSC	OS	Median	II,III,IV	0.140	0.732	.001	14	view →
LIHC	OS	Median	All	0.015	0.784	<.001	12	view →
ESCA	OS	Median	All	0.141	0.700	.001	9	view →
ACC	OS	Median	All	0.118	0.624	.038	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

KRTAP9-4–BLCA (OS)

Open the BLCA breakdown →